News

Fortress Biotech Celebrates Impressive Growth in Q3 Revenue

Fortress Biotech Celebrates Impressive Growth in Q3 Revenue

Fortress Biotech's Strong Revenue Growth

Fortress Biotech, Inc. (NASDAQ: FBIO) has revealed remarkable financial results for its third quarter. The total net revenue rose by 20.5%, reaching $17.6 million, compared to the previous year. This growth underscores the company’s expanding footprint in the biopharmaceutical sector.

Strategic Acquisitions and Partnerships

In a significant move, Fortress's subsidiary, Checkpoint Therapeutics, was acquired by Sun Pharmaceutical. Fortress received around $28 million during the closing of this deal, alongside potential future earnings via a contingent value right (CVR) and a 2.5% royalty on sales of the therapeutic UNLOXCYT™ (cosibelimab-ipdl).

Updates on Dotinurad Development

Dotinurad, a notable next-generation URAT1 inhibitor making strides in two Phase 3 clinical trials, is being closely watched. The backing of Crystalys Therapeutics with a recent $205 million Series A financing signals strong market confidence in the drug’s safety and efficacy potential.

CEO's Insights on Growth

Lindsay A. Rosenwald, M.D., the Chairman and CEO, articulated that Fortress's recent strategic milestones reinforce their diverse business model and enhance shareholder value.

Recent acquisitions validate Fortress's innovative approach, particularly the Checkpoint acquisition which has positioned the company positively in the market.

Progress in Clinical Trials

The advancement of dotinurad in clinical trials speaks to Fortress's commitment to developing treatments that may revolutionize gout therapy. The outcomes from these trials are highly anticipated.

Updates on Emrosi's Market Performance

Moreover, the successful launch of Emrosi™, the treatment for rosacea, has shown strong commercial performance. Journey Medical Corporation, a subsidiary of Fortress, reported a revenue increase to $17.0 million in Q3 2025, which is a significant climb from $14.6 million during the same quarter last year.

Future Outlook

Fortress aims to continue its disciplined focus on capital allocation and advancement of high-impact assets. The company’s pipeline holds the promise of delivering innovative treatments, thus addressing unmet needs in various therapeutic areas.

Frequently Asked Questions

What is Fortress Biotech's revenue growth in Q3 2025?

Fortress Biotech reported a revenue growth of 20.5%, with total net revenue reaching $17.6 million compared to the previous year.

What recent acquisition did Fortress Biotech announce?

Fortress's subsidiary, Checkpoint Therapeutics, was acquired by Sun Pharmaceutical for around $28 million, with potential future earnings through CVR and royalties.

What are the latest updates on dotinurad?

Dotinurad is advancing in Phase 3 clinical trials and is supported by a significant investment from Crystalys, reflecting confidence in its potential.

How well is Emrosi performing in the market?

Journey Medical, which markets Emrosi, reported a substantial increase in revenue to $17 million in Q3 2025.

What are Fortress Biotech's future plans?

Fortress plans to focus on disciplined capital allocation and the advancement of innovative therapies to meet patient needs.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 4

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 6

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 3

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 1

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 4

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 2

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Click Fraud Trends in EMEA: Insightful Data Report

Updated Category News Views 153

Introduction to Click Fraud in EMEA In the digital age, understanding the landscape of click fraud has become crucial for businesses engaging in online advertising. Recent findings have illuminated the extent of click fraud in the EMEA region, showcasing significant statistics that could impact advertisers and digital marketers alike. This article delves into the insights...

Continue Reading
EPR Properties Updates on Third Quarter 2024 Financial Results

Updated Category News Views 88

EPR Properties Reports Strong Third Quarter Results EPR Properties (NYSE:EPR) has recently released its operating results for the third quarter. The data highlighted a promising performance across various metrics, indicating effective management strategies and a strong investment pipeline. Financial Overview For the third quarter, EPR Properties reported total revenue of...

Continue Reading
Exploring Recent Options Strategies in Impinj: Insights and Trends

Updated Category News Views 191

Understanding the Current Options Trading Landscape for Impinj In recent times, it seems that major investors are adopting a cautious stance towards Impinj (NASDAQ: PI). It is important for those involved in the market to pay attention to this shift. Observations of the public options markets reveal some notable movements that might indicate potential developments around...

Continue Reading
Snap-On's Financial Landscape: Insights and Future Growth Prospects

Updated Category News Views 93

Snap-On Holds Steady Amid Mixed Quarter Results Baird has recently reaffirmed a Neutral rating on Snap-On (NYSE: SNA) while raising the price target to $290, an increase from the previous $275. This change in outlook follows Snap-On's second quarter performance, which revealed a blend of outcomes across different segments. During this quarter, Snap-On encountered...

Continue Reading
Drone Technology Transformation Fuels Growth in Surveying Markets

Updated Category News Views 160

Drone Technology Revolutionizes Industrial Surveying The drone surveying market is rapidly evolving, driven by an increasing demand for aerial intelligence and precise mapping across various sectors including agriculture, construction, mining, and environmental monitoring. These advancements allow businesses to enhance operations and make crucial real-time decisions using...

Continue Reading